GlassScriptPhysician profile
Meredith K Molnar
NPI 1265961973
$4,145.83
in general payments reported to CMS, 2019-2025
31 companies · $773 in 2025
The $773 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $314 · 2022: $880 · 2023: $1,131 · 2024: $1,047 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,951.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $825.66 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $615.11 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $548.81 | 2021-2025 | |
| Novo Nordisk INC | $500.64 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $334.23 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.27 | 2022-2025 | Jardiance |
| Pfizer INC. | $158.12 | 2023-2025 | |
| Astellas Pharma US INC | $87.16 | 2023-2025 | Veozah, Myrbetriq |
| Insulet Corporation | $77.61 | 2022-2025 | Omnipod |
| Medtronic, INC. | $75.00 | 2022 | |
| Glaxosmithkline, LLC. | $59.65 | 2022-2023 | Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $59.11 | 2022 | |
| Amgen INC. | $50.84 | 2023-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.11 | 2022-2024 | Xifaxan |
| Corium, LLC | $37.77 | 2023 | Azstarys |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $37.74 | 2022 | |
| Tris Pharma INC | $37.44 | 2023 | Dyanavel Xr |
| Abbott Laboratories | $35.14 | 2021-2022 | |
| Halozyme INC | $32.10 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.05 | 2023-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $24.96 | 2024 | |
| Antares Pharma, INC. | $22.24 | 2023 | Nocdurna, Tlando, Xyosted |
| Dynavax Technologies Corporation | $22.23 | 2023 | Heplisav-B |
| Dexcom, INC. | $19.45 | 2023 | Dexcom G6 Transmitter |
| Agios Pharmaceuticals, INC. | $18.50 | 2025 | Pyrukynd |
| Lundbeck LLC | $17.65 | 2025 | Rexulti |
| Exact Sciences Corporation | $17.32 | 2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $17.16 | 2022 | |
| Edwards Lifesciences Corporation | $15.63 | 2022 | |
| Merck Sharp & Dohme LLC | $15.15 | 2022 | |
| Inspire Medical Systems, INC. | $14.98 | 2023 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Molnar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.